<DOC>
	<DOCNO>NCT02611960</DOCNO>
	<brief_summary>This study pembrolizumab ( MK-3475 ) versus standard care ( SOC ) treatment ( capecitabine , gemcitabine , docetaxel ) treatment recurrent metastatic nasopharyngeal cancer ( NPC ) . Participants randomly assign receive either pembrolizumab Investigator 's choice standard treatment . The primary study hypothesis pembrolizumab treatment prolongs progression-free survival ( PFS ) overall survival ( OS ) compare SOC treatment .</brief_summary>
	<brief_title>Study Pembrolizumab ( MK-3475 ) Platinum Pre-treated Recurrent/Metastatic Nasopharyngeal Cancer ( MK-3475-122 , KEYNOTE-122 )</brief_title>
	<detailed_description />
	<mesh_term>Nasopharyngeal Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Pembrolizumab</mesh_term>
	<criteria>Histologically confirm nonkeratinizing differentiate NPC undifferentiated NPC Metastatic disease incurable locally recurrent disease Treatment prior platinum therapy Tumor tissue available program cell death ligand 1 ( PDL1 ) test Measurable disease base RECIST 1.1 Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Adequate organ function Male female participant childbearing potential must willing use adequate method contraception start first dose study drug 180 day last dose study drug Life expectancy least 3 month Disease suitable local therapy administer curative intent Participants previously treat recurrent/metastatic set 1 3 SOC therapy study ( i.e. , docetaxel , capecitabine , gemcitabine ) may receive therapy randomize SOC arm . Additionally , participant previously treat recurrent/metastatic set 3 SOC therapy exclude study . Currently participate participate study investigational agent use investigational device within 4 week prior first dose study drug Diagnosis immunodeficiency receive systemic steroid therapy form immunosuppressive therapy within 7 day prior first dose study drug Not recovered adverse event due therapy 4 week earlier Prior anticancer monoclonal antibody ( mAb ) therapy within 4 week prior Study Day 1 , recover adverse event Prior chemotherapy , target small molecule therapy , radiation therapy within 2 week prior Study Day 1 Diagnosed and/or treat additional malignancy within 5 year randomization , exception curativelytreated basal cell squamous cell carcinoma skin , and/or curativelyresected situ cervical and/or breast carcinoma Active autoimmune disease require systemic therapy past 2 year modify agent , corticosteroid , immunosuppressive agent Active central nervous system metastases and/or carcinomatous meningitis History noninfectious pneumonitis require steroid current pneumonitis Active infection require systemic therapy Pregnant , breastfeeding , expect conceive father child within project duration trial , start screen visit 120180 day last dose study drug accord local standard care Prior therapy antiprogrammed cell death1 ( PD1 ) antiPD1L1 L2 therapy previously participate Merck pembrolizumab ( MK3475 ) study Human immunodeficiency virus ( HIV ) positive Hepatitis B C positive Live vaccine within 30 day plan start study drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>PD-1</keyword>
	<keyword>PD1</keyword>
	<keyword>PD-L1</keyword>
	<keyword>PDL1</keyword>
</DOC>